Drugs / 2-hydroxybenzoylaminooctanoate
2-hydroxybenzoylaminooctanoate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04781725 | Mar 2021 → Mar 2022 | breast cancer | Ottawa Hospital Research Institute | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2023-09-07 | Intensity Therapeutics, Inc. | Regulatory Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma intensitytherapeutics.com ↗
the US Food and Drug Administration's Office of Orphan Products Development has granted orphan-drug designation for the treatment of soft tissue sarcoma (STS) to the three active moieties comprising INT230-6, cisplatin, vinblastine sulfate, and the diffusion enhancer SHAO-FA (8-((2-hydroxybenzoyl) amino)octanoate). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2023-09-07 | Intensity Therapeutics, Inc. | Intensity Therapeutics Receives Orphan Drug Designation for the three key ingredients in INT230-6 for the Treatment of Soft Tissue Sarcoma intensitytherapeutics.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 2-hydroxybenzoylaminooctanoate | “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ |
| Known as | 2-hydroxybenzoylaminooctanoate (SAHO) | “2-hydroxybenzoylaminooctanoate (SAHO)” NCT04781725 ↗ |
| Known as | SHAO | “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ |
| Known as | SHAO-FA | “INT230-6 is a formulation of two well known chemotherapeutic agents, cisplatin (0.5mg/mL) and vinblastine sulfate (0.1mg/mL), combined with 2-hydroxybenzoylaminooctanoate (also...” NCT04781725 ↗ |